LINK . SPRINGER . COM {}

Matching Content Categories {📚}

• Science
• Health & Fitness
• Education

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

The income method remains a mystery to us.

While many websites aim to make money, others are created to share knowledge or showcase creativity. People build websites for various reasons. This could be one of them. Link.springer.com could be getting rich in stealth mode, or the way it's monetizing isn't detectable.

Keywords {🔍}

article, cancer, cells, google, scholar, cas, pubmed, regulatory, cyclophosphamide, metronomic, ghiringhelli, patients, françois, tumor, immunotherapy, cdcd, cell, menard, zitvogel, therapy, chemotherapy, immune, res, privacy, cookies, content, functions, puig, martin, solary, chauffert, access, immunol, blood, author, function, data, information, publish, search, regimen, roux, treatment, france, log, journal, research, immunology, september, cedric,

Topics {✒️}

t-cell-dependent immune defense month download article/chapter human regulatory cd4+cd25+ late-stage ovarian cancer eric solary cyclophosphamide-resistant murine tumor axel le cesne article cancer immunology faculté de médecine author information authors cd4+cd25+ regulatory regulatory cd4+cd25+ t-suppressor function metronomic chemotherapy regimens full article pdf tumor-induced tolerance reducing tumor angiogenesis cd4+cd25hi regulatory privacy choices/manage cookies specific antitumor immunotherapy metronomic regimen tumor-bearing rodents affect tumor angiogenesis work anticancer immunotherapy author correspondence enhanced immune response low dose cyclophosphamide low-dose cyclophosphamide cyclophosphamide induces type check access instant access article ghiringhelli optimal biologic dose nk effector functions interferon alpha-induced intermittent bolus cyclophosphamide european economic area innate killing activities related subjects facs-isolated populations conejo-garcia jr exosome-based vaccines maximum antiangiogenic activity chronic lymphocytic leukaemia institut gustave roussy nk cells leading iterative low dosing conditions privacy policy predicts reduced survival murine melanoma model

Questions {❓}

• Gasparini G (2001) Metronomic scheduling: the future of chemotherapy?
• T-cell mediated anti-tumor immunity after photodynamic therapy: why does it not always work and how can we improve it?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients
         description:CD4+CD25+ regulatory T cells are involved in the prevention of autoimmune diseases and in tumor-induced tolerance. We previously demonstrated in tumor-bearing rodents that one injection of cyclophosphamide could significantly decrease both numbers and suppressive functions of regulatory T cells, facilitating vaccine-induced tumor rejection. In humans, iterative low dosing of cyclophosphamide, referred to as “metronomic” therapy, has recently been used in patients with advanced chemotherapy resistant cancers with the aim of reducing tumor angiogenesis. Here we show that oral administration of metronomic cyclophosphamide in advanced cancer patients induces a profound and selective reduction of circulating regulatory T cells, associated with a suppression of their inhibitory functions on conventional T cells and NK cells leading to a restoration of peripheral T cell proliferation and innate killing activities. Therefore, metronomic regimen of cyclophosphamide does not only affect tumor angiogenesis but also strongly curtails immunosuppressive regulatory T cells, favoring a better control of tumor progression. Altogether these data support cyclophosphamide regimen as a valuable treatment for reducing tumor-induced immune tolerance before setting to work anticancer immunotherapy.
         datePublished:2006-09-08T00:00:00Z
         dateModified:2006-09-08T00:00:00Z
         pageStart:641
         pageEnd:648
         sameAs:https://doi.org/10.1007/s00262-006-0225-8
         keywords:
            Cyclophosphamide
            Regulatory T cell
            Metronomic treatment
            Immunotherapy
            Oncology
            Immunology
            Cancer Research
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-006-0225-8/MediaObjects/262_2006_225_Fig1a-b_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-006-0225-8/MediaObjects/262_2006_225_Fig1c_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-006-0225-8/MediaObjects/262_2006_225_Fig2_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-006-0225-8/MediaObjects/262_2006_225_Fig3_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-006-0225-8/MediaObjects/262_2006_225_Fig4_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-006-0225-8/MediaObjects/262_2006_225_Fig5_HTML.gif
         isPartOf:
            name:Cancer Immunology, Immunotherapy
            issn:
               1432-0851
               0340-7004
            volumeNumber:56
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer-Verlag
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:François Ghiringhelli
               affiliation:
                     name:Unité INSERM 517, Faculté de Médecine
                     address:
                        name:Unité INSERM 517, Faculté de Médecine, Dijon, France
                        type:PostalAddress
                     type:Organization
                     name:Centre de Lutte contre le Cancer
                     address:
                        name:Centre de Lutte contre le Cancer, Dijon, France
                        type:PostalAddress
                     type:Organization
                     name:Villejuif, Faculté de Médecine Kremlin Bicêtre
                     address:
                        name:ERM-0208 INSERM, Institut Gustave Roussy, Villejuif, Faculté de Médecine Kremlin Bicêtre, Paris, France
                        type:PostalAddress
                     type:Organization
                     name:Villejuif, Faculté de Médecine Kremlin Bicêtre
                     address:
                        name:Department of Medicine, Institut Gustave Roussy, Villejuif, Faculté de Médecine Kremlin Bicêtre, Paris, France
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Cedric Menard
               affiliation:
                     name:Villejuif, Faculté de Médecine Kremlin Bicêtre
                     address:
                        name:ERM-0208 INSERM, Institut Gustave Roussy, Villejuif, Faculté de Médecine Kremlin Bicêtre, Paris, France
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Pierre Emmanuel Puig
               affiliation:
                     name:Unité INSERM 517, Faculté de Médecine
                     address:
                        name:Unité INSERM 517, Faculté de Médecine, Dijon, France
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Sylvain Ladoire
               affiliation:
                     name:Centre de Lutte contre le Cancer
                     address:
                        name:Centre de Lutte contre le Cancer, Dijon, France
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Stephan Roux
               affiliation:
                     name:Villejuif, Faculté de Médecine Kremlin Bicêtre
                     address:
                        name:ERM-0208 INSERM, Institut Gustave Roussy, Villejuif, Faculté de Médecine Kremlin Bicêtre, Paris, France
                        type:PostalAddress
                     type:Organization
               type:Person
               name:François Martin
               affiliation:
                     name:Unité INSERM 517, Faculté de Médecine
                     address:
                        name:Unité INSERM 517, Faculté de Médecine, Dijon, France
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Eric Solary
               affiliation:
                     name:Unité INSERM 517, Faculté de Médecine
                     address:
                        name:Unité INSERM 517, Faculté de Médecine, Dijon, France
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Axel Le Cesne
               affiliation:
                     name:Villejuif, Faculté de Médecine Kremlin Bicêtre
                     address:
                        name:Department of Medicine, Institut Gustave Roussy, Villejuif, Faculté de Médecine Kremlin Bicêtre, Paris, France
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Laurence Zitvogel
               affiliation:
                     name:Villejuif, Faculté de Médecine Kremlin Bicêtre
                     address:
                        name:ERM-0208 INSERM, Institut Gustave Roussy, Villejuif, Faculté de Médecine Kremlin Bicêtre, Paris, France
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Bruno Chauffert
               affiliation:
                     name:Unité INSERM 517, Faculté de Médecine
                     address:
                        name:Unité INSERM 517, Faculté de Médecine, Dijon, France
                        type:PostalAddress
                     type:Organization
                     name:Centre de Lutte contre le Cancer
                     address:
                        name:Centre de Lutte contre le Cancer, Dijon, France
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients
      description:CD4+CD25+ regulatory T cells are involved in the prevention of autoimmune diseases and in tumor-induced tolerance. We previously demonstrated in tumor-bearing rodents that one injection of cyclophosphamide could significantly decrease both numbers and suppressive functions of regulatory T cells, facilitating vaccine-induced tumor rejection. In humans, iterative low dosing of cyclophosphamide, referred to as “metronomic” therapy, has recently been used in patients with advanced chemotherapy resistant cancers with the aim of reducing tumor angiogenesis. Here we show that oral administration of metronomic cyclophosphamide in advanced cancer patients induces a profound and selective reduction of circulating regulatory T cells, associated with a suppression of their inhibitory functions on conventional T cells and NK cells leading to a restoration of peripheral T cell proliferation and innate killing activities. Therefore, metronomic regimen of cyclophosphamide does not only affect tumor angiogenesis but also strongly curtails immunosuppressive regulatory T cells, favoring a better control of tumor progression. Altogether these data support cyclophosphamide regimen as a valuable treatment for reducing tumor-induced immune tolerance before setting to work anticancer immunotherapy.
      datePublished:2006-09-08T00:00:00Z
      dateModified:2006-09-08T00:00:00Z
      pageStart:641
      pageEnd:648
      sameAs:https://doi.org/10.1007/s00262-006-0225-8
      keywords:
         Cyclophosphamide
         Regulatory T cell
         Metronomic treatment
         Immunotherapy
         Oncology
         Immunology
         Cancer Research
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-006-0225-8/MediaObjects/262_2006_225_Fig1a-b_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-006-0225-8/MediaObjects/262_2006_225_Fig1c_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-006-0225-8/MediaObjects/262_2006_225_Fig2_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-006-0225-8/MediaObjects/262_2006_225_Fig3_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-006-0225-8/MediaObjects/262_2006_225_Fig4_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-006-0225-8/MediaObjects/262_2006_225_Fig5_HTML.gif
      isPartOf:
         name:Cancer Immunology, Immunotherapy
         issn:
            1432-0851
            0340-7004
         volumeNumber:56
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer-Verlag
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:François Ghiringhelli
            affiliation:
                  name:Unité INSERM 517, Faculté de Médecine
                  address:
                     name:Unité INSERM 517, Faculté de Médecine, Dijon, France
                     type:PostalAddress
                  type:Organization
                  name:Centre de Lutte contre le Cancer
                  address:
                     name:Centre de Lutte contre le Cancer, Dijon, France
                     type:PostalAddress
                  type:Organization
                  name:Villejuif, Faculté de Médecine Kremlin Bicêtre
                  address:
                     name:ERM-0208 INSERM, Institut Gustave Roussy, Villejuif, Faculté de Médecine Kremlin Bicêtre, Paris, France
                     type:PostalAddress
                  type:Organization
                  name:Villejuif, Faculté de Médecine Kremlin Bicêtre
                  address:
                     name:Department of Medicine, Institut Gustave Roussy, Villejuif, Faculté de Médecine Kremlin Bicêtre, Paris, France
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Cedric Menard
            affiliation:
                  name:Villejuif, Faculté de Médecine Kremlin Bicêtre
                  address:
                     name:ERM-0208 INSERM, Institut Gustave Roussy, Villejuif, Faculté de Médecine Kremlin Bicêtre, Paris, France
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Pierre Emmanuel Puig
            affiliation:
                  name:Unité INSERM 517, Faculté de Médecine
                  address:
                     name:Unité INSERM 517, Faculté de Médecine, Dijon, France
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Sylvain Ladoire
            affiliation:
                  name:Centre de Lutte contre le Cancer
                  address:
                     name:Centre de Lutte contre le Cancer, Dijon, France
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Stephan Roux
            affiliation:
                  name:Villejuif, Faculté de Médecine Kremlin Bicêtre
                  address:
                     name:ERM-0208 INSERM, Institut Gustave Roussy, Villejuif, Faculté de Médecine Kremlin Bicêtre, Paris, France
                     type:PostalAddress
                  type:Organization
            type:Person
            name:François Martin
            affiliation:
                  name:Unité INSERM 517, Faculté de Médecine
                  address:
                     name:Unité INSERM 517, Faculté de Médecine, Dijon, France
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Eric Solary
            affiliation:
                  name:Unité INSERM 517, Faculté de Médecine
                  address:
                     name:Unité INSERM 517, Faculté de Médecine, Dijon, France
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Axel Le Cesne
            affiliation:
                  name:Villejuif, Faculté de Médecine Kremlin Bicêtre
                  address:
                     name:Department of Medicine, Institut Gustave Roussy, Villejuif, Faculté de Médecine Kremlin Bicêtre, Paris, France
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Laurence Zitvogel
            affiliation:
                  name:Villejuif, Faculté de Médecine Kremlin Bicêtre
                  address:
                     name:ERM-0208 INSERM, Institut Gustave Roussy, Villejuif, Faculté de Médecine Kremlin Bicêtre, Paris, France
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Bruno Chauffert
            affiliation:
                  name:Unité INSERM 517, Faculté de Médecine
                  address:
                     name:Unité INSERM 517, Faculté de Médecine, Dijon, France
                     type:PostalAddress
                  type:Organization
                  name:Centre de Lutte contre le Cancer
                  address:
                     name:Centre de Lutte contre le Cancer, Dijon, France
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Cancer Immunology, Immunotherapy
      issn:
         1432-0851
         0340-7004
      volumeNumber:56
Organization:
      name:Springer-Verlag
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Unité INSERM 517, Faculté de Médecine
      address:
         name:Unité INSERM 517, Faculté de Médecine, Dijon, France
         type:PostalAddress
      name:Centre de Lutte contre le Cancer
      address:
         name:Centre de Lutte contre le Cancer, Dijon, France
         type:PostalAddress
      name:Villejuif, Faculté de Médecine Kremlin Bicêtre
      address:
         name:ERM-0208 INSERM, Institut Gustave Roussy, Villejuif, Faculté de Médecine Kremlin Bicêtre, Paris, France
         type:PostalAddress
      name:Villejuif, Faculté de Médecine Kremlin Bicêtre
      address:
         name:Department of Medicine, Institut Gustave Roussy, Villejuif, Faculté de Médecine Kremlin Bicêtre, Paris, France
         type:PostalAddress
      name:Villejuif, Faculté de Médecine Kremlin Bicêtre
      address:
         name:ERM-0208 INSERM, Institut Gustave Roussy, Villejuif, Faculté de Médecine Kremlin Bicêtre, Paris, France
         type:PostalAddress
      name:Unité INSERM 517, Faculté de Médecine
      address:
         name:Unité INSERM 517, Faculté de Médecine, Dijon, France
         type:PostalAddress
      name:Centre de Lutte contre le Cancer
      address:
         name:Centre de Lutte contre le Cancer, Dijon, France
         type:PostalAddress
      name:Villejuif, Faculté de Médecine Kremlin Bicêtre
      address:
         name:ERM-0208 INSERM, Institut Gustave Roussy, Villejuif, Faculté de Médecine Kremlin Bicêtre, Paris, France
         type:PostalAddress
      name:Unité INSERM 517, Faculté de Médecine
      address:
         name:Unité INSERM 517, Faculté de Médecine, Dijon, France
         type:PostalAddress
      name:Unité INSERM 517, Faculté de Médecine
      address:
         name:Unité INSERM 517, Faculté de Médecine, Dijon, France
         type:PostalAddress
      name:Villejuif, Faculté de Médecine Kremlin Bicêtre
      address:
         name:Department of Medicine, Institut Gustave Roussy, Villejuif, Faculté de Médecine Kremlin Bicêtre, Paris, France
         type:PostalAddress
      name:Villejuif, Faculté de Médecine Kremlin Bicêtre
      address:
         name:ERM-0208 INSERM, Institut Gustave Roussy, Villejuif, Faculté de Médecine Kremlin Bicêtre, Paris, France
         type:PostalAddress
      name:Unité INSERM 517, Faculté de Médecine
      address:
         name:Unité INSERM 517, Faculté de Médecine, Dijon, France
         type:PostalAddress
      name:Centre de Lutte contre le Cancer
      address:
         name:Centre de Lutte contre le Cancer, Dijon, France
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:François Ghiringhelli
      affiliation:
            name:Unité INSERM 517, Faculté de Médecine
            address:
               name:Unité INSERM 517, Faculté de Médecine, Dijon, France
               type:PostalAddress
            type:Organization
            name:Centre de Lutte contre le Cancer
            address:
               name:Centre de Lutte contre le Cancer, Dijon, France
               type:PostalAddress
            type:Organization
            name:Villejuif, Faculté de Médecine Kremlin Bicêtre
            address:
               name:ERM-0208 INSERM, Institut Gustave Roussy, Villejuif, Faculté de Médecine Kremlin Bicêtre, Paris, France
               type:PostalAddress
            type:Organization
            name:Villejuif, Faculté de Médecine Kremlin Bicêtre
            address:
               name:Department of Medicine, Institut Gustave Roussy, Villejuif, Faculté de Médecine Kremlin Bicêtre, Paris, France
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Cedric Menard
      affiliation:
            name:Villejuif, Faculté de Médecine Kremlin Bicêtre
            address:
               name:ERM-0208 INSERM, Institut Gustave Roussy, Villejuif, Faculté de Médecine Kremlin Bicêtre, Paris, France
               type:PostalAddress
            type:Organization
      name:Pierre Emmanuel Puig
      affiliation:
            name:Unité INSERM 517, Faculté de Médecine
            address:
               name:Unité INSERM 517, Faculté de Médecine, Dijon, France
               type:PostalAddress
            type:Organization
      name:Sylvain Ladoire
      affiliation:
            name:Centre de Lutte contre le Cancer
            address:
               name:Centre de Lutte contre le Cancer, Dijon, France
               type:PostalAddress
            type:Organization
      name:Stephan Roux
      affiliation:
            name:Villejuif, Faculté de Médecine Kremlin Bicêtre
            address:
               name:ERM-0208 INSERM, Institut Gustave Roussy, Villejuif, Faculté de Médecine Kremlin Bicêtre, Paris, France
               type:PostalAddress
            type:Organization
      name:François Martin
      affiliation:
            name:Unité INSERM 517, Faculté de Médecine
            address:
               name:Unité INSERM 517, Faculté de Médecine, Dijon, France
               type:PostalAddress
            type:Organization
      name:Eric Solary
      affiliation:
            name:Unité INSERM 517, Faculté de Médecine
            address:
               name:Unité INSERM 517, Faculté de Médecine, Dijon, France
               type:PostalAddress
            type:Organization
      name:Axel Le Cesne
      affiliation:
            name:Villejuif, Faculté de Médecine Kremlin Bicêtre
            address:
               name:Department of Medicine, Institut Gustave Roussy, Villejuif, Faculté de Médecine Kremlin Bicêtre, Paris, France
               type:PostalAddress
            type:Organization
      name:Laurence Zitvogel
      affiliation:
            name:Villejuif, Faculté de Médecine Kremlin Bicêtre
            address:
               name:ERM-0208 INSERM, Institut Gustave Roussy, Villejuif, Faculté de Médecine Kremlin Bicêtre, Paris, France
               type:PostalAddress
            type:Organization
      name:Bruno Chauffert
      affiliation:
            name:Unité INSERM 517, Faculté de Médecine
            address:
               name:Unité INSERM 517, Faculté de Médecine, Dijon, France
               type:PostalAddress
            type:Organization
            name:Centre de Lutte contre le Cancer
            address:
               name:Centre de Lutte contre le Cancer, Dijon, France
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Unité INSERM 517, Faculté de Médecine, Dijon, France
      name:Centre de Lutte contre le Cancer, Dijon, France
      name:ERM-0208 INSERM, Institut Gustave Roussy, Villejuif, Faculté de Médecine Kremlin Bicêtre, Paris, France
      name:Department of Medicine, Institut Gustave Roussy, Villejuif, Faculté de Médecine Kremlin Bicêtre, Paris, France
      name:ERM-0208 INSERM, Institut Gustave Roussy, Villejuif, Faculté de Médecine Kremlin Bicêtre, Paris, France
      name:Unité INSERM 517, Faculté de Médecine, Dijon, France
      name:Centre de Lutte contre le Cancer, Dijon, France
      name:ERM-0208 INSERM, Institut Gustave Roussy, Villejuif, Faculté de Médecine Kremlin Bicêtre, Paris, France
      name:Unité INSERM 517, Faculté de Médecine, Dijon, France
      name:Unité INSERM 517, Faculté de Médecine, Dijon, France
      name:Department of Medicine, Institut Gustave Roussy, Villejuif, Faculté de Médecine Kremlin Bicêtre, Paris, France
      name:ERM-0208 INSERM, Institut Gustave Roussy, Villejuif, Faculté de Médecine Kremlin Bicêtre, Paris, France
      name:Unité INSERM 517, Faculté de Médecine, Dijon, France
      name:Centre de Lutte contre le Cancer, Dijon, France
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(98)

• What is the monthly revenue of https://www.springernature.com/gp/authors?
• See how much https://link.springernature.com/home/ makes per month
• How much income does https://order.springer.com/public/cart have?
• How much income does https://submission.nature.com/new-submission/262/3 have?
• How much cash flow does https://www.springernature.com/gp/librarians/licensing/agc/journals have monthly?
• How much revenue does https://doi.org/10.1016%2Fj.clim.2005.02.018 produce monthly?
• Get to know what's the income of http://scholar.google.com/scholar_lookup?&title=Functional%20analysis%20of%20highly%20defined%2C%20FACS-isolated%20populations%20of%20human%20regulatory%20CD4%2BCD25%2B%20T%20cells&journal=Clin%20Immunol&doi=10.1016%2Fj.clim.2005.02.018&volume=115&pages=S10-S18&publication_year=2005&author=Baecher-Allan%2CC&author=Wolf%2CE&author=Hafler%2CDA
• How profitable is https://doi.org/10.1016%2FS0092-8674%2800%2980856-9?
• What's the financial outcome of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10850488?
• What's the profit of http://scholar.google.com/scholar_lookup?&title=Regulatory%20T%20cells%3A%20key%20controllers%20of%20immunologic%20self-tolerance&journal=Cell&doi=10.1016%2FS0092-8674%2800%2980856-9&volume=101&pages=455-458&publication_year=2000&author=Sakaguchi%2CS?
• How much income does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=11751377 have?
• What's the total monthly financial gain of http://scholar.google.com/scholar_lookup?&title=Depletion%20of%20CD25%28%2B%29%20CD4%28%2B%29%20T%20cells%20and%20treatment%20with%20tyrosinase-related%20protein%202-transduced%20dendritic%20cells%20enhance%20the%20interferon%20alpha-induced%2C%20CD8%28%2B%29%20T-cell-dependent%20immune%20defense%20of%20B16%20melanoma&journal=Cancer%20Res&volume=61&pages=8643-8646&publication_year=2001&author=Steitz%2CJ&author=Bruck%2CJ&author=Lenz%2CJ&author=Knop%2CJ&author=Tuting%2CT?
• What's the financial gain of https://doi.org/10.1002%2Feji.200324181?
• What's the monthly income of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=14768038?
• Financial intake of http://scholar.google.com/scholar_lookup?&title=CD4%2BCD25%2B%20regulatory%20T%20cells%20suppress%20tumor%20immunity%20but%20are%20sensitive%20to%20cyclophosphamide%20which%20allows%20immunotherapy%20of%20established%20tumors%20to%20be%20curative&journal=Eur%20J%20Immunol&doi=10.1002%2Feji.200324181&volume=34&pages=336-344&publication_year=2004&author=Ghiringhelli%2CF&author=Larmonier%2CN&author=Schmitt%2CE&author=Parcellier%2CA&author=Cathelin%2CD&author=Garrido%2CC&author=Chauffert%2CB&author=Solary%2CE&author=Bonnotte%2CB&author=Martin%2CF
• What's the income of https://doi.org/10.1084%2Fjem.20050463?
• How much profit does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=16186184 make?
• How much profit does http://scholar.google.com/scholar_lookup?&title=Tumor%20cells%20convert%20immature%20myeloid%20dendritic%20cells%20into%20TGF-%CE%B2-secreting%20cells%20inducing%20CD4%2BCD25%2B%20regulatory%20T%20cell%20proliferation&journal=J%20Exp%20Med&doi=10.1084%2Fjem.20050463&volume=202&pages=919-929&publication_year=2005&author=Ghiringhelli%2CF&author=Puig%2CPE&author=Roux%2CS&author=Parcellier%2CA&author=Schmitt%2CE&author=Solary%2CE&author=Kroemer%2CG&author=Martin%2CF&author=Chauffert%2CB&author=Zitvogel%2CL make?
• How much money does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=11406550 generate?
• Learn about the earnings of http://scholar.google.com/scholar_lookup?&title=Regulatory%20CD4%2BCD25%2B%20T%20cells%20in%20tumors%20from%20patients%20with%20early-stage%20non-small%20cell%20lung%20cancer%20and%20late-stage%20ovarian%20cancer&journal=Cancer%20Res&volume=61&pages=4766-4772&publication_year=2001&author=Woo%2CEY&author=Chu%2CCS&author=Goletz%2CTJ&author=Schlienger%2CK&author=Yeh%2CH&author=Coukos%2CG&author=Rubin%2CSC&author=Kaiser%2CLR&author=June%2CCH
• http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=12193750's financial summary
• Explore the financials of http://scholar.google.com/scholar_lookup?&title=Prevalence%20of%20regulatory%20T%20cells%20is%20increased%20in%20peripheral%20blood%20and%20tumor%20microenvironment%20of%20patients%20with%20pancreas%20or%20breast%20adenocarcinoma&journal=J%20Immunol&volume=169&pages=2756-2761&publication_year=2002&author=Liyanage%2CUK&author=Moore%2CTT&author=Joo%2CHG&author=Tanaka%2CY&author=Herrmann%2CV&author=Doherty%2CG&author=Drebin%2CJA&author=Strasberg%2CSM&author=Eberlein%2CTJ&author=Goedegebuure%2CPS&author=Linehan%2CDC
• What's the financial intake of https://doi.org/10.1038%2Fnm1093?
• What's http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=15322536's gross income?
• What's http://scholar.google.com/scholar_lookup?&title=Specific%20recruitment%20of%20regulatory%20T%20cells%20in%20ovarian%20carcinoma%20fosters%20immune%20privilege%20and%20predicts%20reduced%20survival&journal=Nat%20Med&doi=10.1038%2Fnm1093&volume=10&pages=942-949&publication_year=2004&author=Curiel%2CTJ&author=Coukos%2CG&author=Zou%2CL&author=Alvarez%2CX&author=Cheng%2CP&author=Mottram%2CP&author=Evdemon-Hogan%2CM&author=Conejo-Garcia%2CJR&author=Zhang%2CL&author=Burow%2CM&author=Zhu%2CY&author=Wei%2CS&author=Kryczek%2CI&author=Daniel%2CB&author=Gordon%2CA&author=Myers%2CL&author=Lackner%2CA&author=Disis%2CML&author=Knutson%2CKL&author=Chen%2CL&author=Zou%2CW's gross income?
• How much does https://doi.org/10.1084%2Fjem.20051511 net monthly?
• What is the earnings of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=16230475?
• Check the income stats for http://scholar.google.com/scholar_lookup?&title=CD4%2BCD25%2B%20regulatory%20T%20cells%20inhibit%20natural%20killer%20cell%20functions%20in%20a%20transforming%20growth%20factor-%CE%B2-dependent%20manner&journal=J%20Exp%20Med&doi=10.1084%2Fjem.20051511&volume=202&pages=1075-1085&publication_year=2005&author=Ghiringhelli%2CF&author=Menard%2CC&author=Terme%2CM&author=Flament%2CC&author=Taieb%2CJ&author=Chaput%2CN&author=Puig%2CPE&author=Novault%2CS&author=Escudier%2CB&author=Vivier%2CE&author=Lecesne%2CA&author=Robert%2CC&author=Blay%2CJY&author=Bernard%2CJ&author=Caillat-Zucman%2CS&author=Freitas%2CA&author=Tursz%2CT&author=Wagner-Ballon%2CO&author=Capron%2CC&author=Vainchencker%2CW&author=Martin%2CF&author=Zitvogel%2CL
• What's the revenue for http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=2522344?
• How much money does http://scholar.google.com/scholar_lookup?&title=Cyclophosphamide-induced%20immunologically%20mediated%20regression%20of%20a%20cyclophosphamide-resistant%20murine%20tumor%3A%20a%20consequence%20of%20eliminating%20precursor%20L3T4%2B%20suppressor%20T-cells&journal=Cancer%20Res&volume=49&pages=1649-1654&publication_year=1989&author=Awwad%2CM&author=North%2CRJ make?
• What's http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=2953413's gross income?
• Income figures for http://scholar.google.com/scholar_lookup?&title=Effect%20of%20low%20dose%20cyclophosphamide%20on%20the%20immune%20system%20of%20cancer%20patients%3A%20reduction%20of%20T-suppressor%20function%20without%20depletion%20of%20the%20CD8%2B%20subset&journal=Cancer%20Res&volume=47&pages=3317-3321&publication_year=1987&author=Berd%2CD&author=Mastrangelo%2CMJ
• How much does https://doi.org/10.1182%2Fblood-2004-06-2410 bring in each month?
• Profit of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=15591121
• http://scholar.google.com/scholar_lookup?&title=Inhibition%20of%20CD4%2B25%2B%20T%20regulatory%20cell%20function%20implicated%20in%20enhanced%20immune%20response%20by%20low-dose%20cyclophosphamide&journal=Blood&doi=10.1182%2Fblood-2004-06-2410&volume=105&pages=2862-2868&publication_year=2005&author=Lutsiak%2CME&author=Semnani%2CRT&author=Pascalis%2CR&author=Kashmiri%2CSV&author=Schlom%2CJ&author=Sabzevari%2CH income
• Learn how profitable http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=16493027 is on a monthly basis
• How much does http://scholar.google.com/scholar_lookup?&title=Chemo-immunotherapy%20of%20tumors%3A%20cyclophosphamide%20synergizes%20with%20exosome-based%20vaccines&journal=J%20Immunol&volume=176&pages=2722-2729&publication_year=2006&author=Taieb%2CJ&author=Chaput%2CN&author=Schartz%2CN&author=Roux%2CS&author=Novault%2CS&author=Menard%2CC&author=Ghiringhelli%2CF&author=Terme%2CM&author=Carpentier%2CAF&author=Darrasse-Jese%2CG&author=Lemonnier%2CF&author=Zitvogel%2CL pull in monthly?
• What's the financial outcome of https://doi.org/10.1016%2FS1470-2045%2801%2900587-3?
• How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=11902515 earn?
• Learn about the earnings of http://scholar.google.com/scholar_lookup?&title=Metronomic%20scheduling%3A%20the%20future%20of%20chemotherapy%3F&journal=Lancet%20Oncol&doi=10.1016%2FS1470-2045%2801%2900587-3&volume=2&pages=733-740&publication_year=2001&author=Gasparini%2CG
• How much income does https://doi.org/10.1182%2Fblood-2005-04-1422 have?
• How much profit does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=15998832 make?
• Check the income stats for http://scholar.google.com/scholar_lookup?&title=Optimal%20biologic%20dose%20of%20metronomic%20chemotherapy%20regimens%20is%20associated%20with%20maximum%20antiangiogenic%20activity&journal=Blood&doi=10.1182%2Fblood-2005-04-1422&volume=106&pages=3058-3061&publication_year=2005&author=Shaked%2CY&author=Emmenegger%2CU&author=Man%2CS&author=Cervi%2CD&author=Bertolini%2CF&author=Ben-David%2CY&author=Kerbel%2CRS
• Financial intake of https://doi.org/10.1002%2Fcncr.11713
• See how much http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=14534880 makes per month
• Learn how profitable http://scholar.google.com/scholar_lookup?&title=Metronomic%20therapy%20with%20cyclophosphamide%20and%20dexamethasone%20for%20prostate%20carcinoma&journal=Cancer&doi=10.1002%2Fcncr.11713&volume=98&pages=1643-1648&publication_year=2003&author=Glode%2CLM&author=Barqawi%2CA&author=Crighton%2CF&author=Crawford%2CED&author=Kerbel%2CR is on a monthly basis
• How much profit does https://doi.org/10.1158%2F0008-5472.CAN-05-0765 generate?
• http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=16103050's revenue stream
• How much income does http://scholar.google.com/scholar_lookup?&title=Low%20dose%20metronomic%20combined%20with%20intermittent%20bolus%20cyclophosphamide%20is%20an%20effective%20long-term%20chemotherapy%20treatment%20strategy&journal=Cancer%20Res&doi=10.1158%2F0008-5472.CAN-05-0765&volume=65&pages=7045-7051&publication_year=2005&author=Shaked%2CY&author=Emmenegger%2CU&author=Francia%2CG&author=Chen%2CL&author=Lee%2CCR&author=Man%2CS&author=Paraghamian%2CA&author=Ben-David%2CY&author=Kerbel%2CRS have?
• What's the financial gain of https://doi.org/10.1182%2Fblood-2005-02-0642?
• What's the profit of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=15914560?
• Income figures for http://scholar.google.com/scholar_lookup?&title=Reduced%20frequencies%20and%20suppressive%20function%20of%20CD4%2BCD25hi%20regulatory%20T%20cells%20in%20patients%20with%20chronic%20lymphocytic%20leukaemia%20after%20therapy%20with%20fludarabine&journal=Blood&doi=10.1182%2Fblood-2005-02-0642&volume=106&pages=2018-2025&publication_year=2005&author=Beyer%2CM&author=Kochanek%2CM&author=Darabi%2CK&author=Endl%2CE&author=Weihrauch%2CMR&author=Knolle%2CPA&author=Classen%2CS&author=Schultze%2CJL
• What's the income of https://doi.org/10.1097%2F01.cji.0000175468.19742.10?
• Get to know what's the income of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=16224276
• How much does http://scholar.google.com/scholar_lookup?&title=Inability%20of%20a%20fusion%20protein%20of%20IL-2%20and%20diphtheria%20toxin%20%28Denileukin%20Diftitox%2C%20DAB389IL-2%2C%20ONTAK%29%20to%20eliminate%20regulatory%20T%20lymphocytes%20in%20patients%20with%20melanoma&journal=J%20Immunother&doi=10.1097%2F01.cji.0000175468.19742.10&volume=28&pages=582-592&publication_year=2005&author=Attia%2CP&author=Maker%2CAV&author=Haworth%2CLR&author=Rogers-Freezer%2CL&author=Rosenberg%2CSA generate monthly?
• How much income is http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=14679003 earning monthly?
• How much revenue does http://scholar.google.com/scholar_lookup?&title=Synergistic%20effect%20of%20metronomic%20dosing%20of%20cyclophosphamide%20combined%20with%20specific%20antitumor%20immunotherapy%20in%20a%20murine%20melanoma%20model&journal=Cancer%20Res&volume=63&pages=8408-8413&publication_year=2003&author=Hermans%2CIF&author=Chong%2CTW&author=Palmowski%2CMJ&author=Harris%2CAL&author=Cerundolo%2CV bring in?
• http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10706870's financial summary
• How much does http://scholar.google.com/scholar_lookup?&title=Cyclophosphamide%20induces%20type%20I%20interferon%20and%20augments%20the%20number%20of%20CD44%28hi%29%20T%20lymphocytes%20in%20mice%3A%20implications%20for%20strategies%20of%20chemoimmunotherapy%20of%20cancer&journal=Blood&volume=95&pages=2024-2030&publication_year=2000&author=Schiavoni%2CG&author=Mattei%2CF&author=Pucchio%2CT&author=Santini%2CSM&author=Bracci%2CL&author=Belardelli%2CF&author=Proietti%2CE pull in?
• What's the revenue for https://citation-needed.springer.com/v2/references/10.1007/s00262-006-0225-8?format=refman&flavour=references?
• Discover the revenue of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Fran%C3%A7ois%20Ghiringhelli
• How profitable is https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Fran%C3%A7ois%20Ghiringhelli%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
• Profit of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Cedric%20Menard
• Financial intake of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Cedric%20Menard%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
• https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Pierre%20Emmanuel%20Puig's total income per month
• What's the profit of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Pierre%20Emmanuel%20Puig%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
• What's the profit of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Sylvain%20Ladoire?
• What's the financial outcome of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Sylvain%20Ladoire%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
• How much does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Stephan%20Roux rake in every month?
• How much revenue does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Stephan%20Roux%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en bring in?
• How much does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Fran%C3%A7ois%20Martin pull in monthly?
• What's the financial intake of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Fran%C3%A7ois%20Martin%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
• What's the financial intake of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Eric%20Solary?
• How much cash flow does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Eric%20Solary%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en have monthly?
• What's the monthly money flow for https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Axel%20Le%20Cesne?
• Profit of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Axel%20Le%20Cesne%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
• What is the monthly revenue of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Laurence%20Zitvogel?
• What's the monthly money flow for https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Laurence%20Zitvogel%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
• https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Bruno%20Chauffert's revenue stream
• Learn how profitable https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Bruno%20Chauffert%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en is on a monthly basis
• How much does https://s100.copyright.com/AppDispatchServlet?title=Metronomic%20cyclophosphamide%20regimen%20selectively%20depletes%20CD4%2BCD25%2B%20regulatory%20T%20cells%20and%20restores%20T%20and%20NK%20effector%20functions%20in%20end%20stage%20cancer%20patients&author=Fran%C3%A7ois%20Ghiringhelli%20et%20al&contentID=10.1007%2Fs00262-006-0225-8©right=Springer-Verlag&publication=0340-7004&publicationDate=2006-09-08&publisherName=SpringerNature&orderBeanReset=true pull in?
• What's the monthly income of https://citation-needed.springer.com/v2/references/10.1007/s00262-006-0225-8?format=refman&flavour=citation?
• Income figures for https://authorservices.springernature.com/go/sn/?utm_source=SNLinkfooter&utm_medium=Web&utm_campaign=SNReferral
• How much does https://www.springernature.com/gp/open-research/about/the-fundamentals-of-open-access-and-open-research pull in monthly?
• How much money does https://www.springernature.com/gp/products generate?
• What's the financial outcome of https://www.springernature.com/gp/librarians?
• How much revenue does https://www.springernature.com/gp/societies generate?
• What is the monthly revenue of https://www.springernature.com/gp/partners?
• What's the total monthly financial gain of https://www.springer.com/?
• What's the revenue for https://www.nature.com/?
• How much money does https://www.biomedcentral.com/ make?
• How much does https://www.palgrave.com/ rake in every month?
• https://www.apress.com/'s revenue stream
• What are the earnings of https://www.springernature.com/gp/legal/ccpa?
• How much does https://www.springernature.com/gp/info/accessibility pull in?
• https://support.springernature.com/en/support/home's financial summary
• What are the earnings of https://support.springernature.com/en/support/solutions/articles/6000255911-subscription-cancellations?
• How much does https://www.springernature.com/ rake in every month?

Analytics and Tracking {📊}

• Google Tag Manager

Libraries {📚}

• Clipboard.js
• Prism.js

CDN Services {📦}

• Crossref